Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics Ltd. (PRNAF)
OTHER OTC:PRNAF
PRNAF Stock Chart & Stats
$0.01
>-$0.01(-47.06%)
At close: 4:00 PM EDT
$0.01
>-$0.01(-47.06%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume10.00K
Average Volume (3M)36.00
Market Cap
$53.67M
Enterprise Value$27.09M
Total Cash (Recent Filing)$49.20M
Total Debt (Recent Filing)$163.91K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding10,875,416,000
10 Day Avg. Volume0
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue7.07
Enterprise Value/Gross Profit7.30
Enterprise Value/Ebitda-1.35
Forecast
1Y Price Target
<$0.01Price Target Upside-29.07% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$1.61M
Bulls Say, Bears Say
Bulls Say
Phase 2 Efficacy & Regulatory ProgressRobust Phase 2 safety and efficacy signals materially de-risk ATH434 and support the planned FDA End-of-Phase-2 meeting and Phase 3 initiation. This durable clinical progress improves the probability of reaching a pivotal trial, strengthens partner interest, and enhances the company's long-term development pathway.
Minimal Financial LeverageExtremely low leverage provides financial flexibility across an expensive clinical development timeline, reducing solvency risk. A strong equity base supports options for strategic partnering or staged equity raises with less refinancing pressure, preserving corporate optionality during Phase 3 planning and execution.
Strong Reported Revenue GrowthA 46% year-over-year revenue increase signals improving top-line traction—likely from grants, collaborations or other non-operating sources—and indicates successful external validation of programs. Sustained growth in reported revenues can bolster runway and make the company more attractive to partners and non-dilutive funders over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow and a steep FCF decline highlight structural cash burn typical of late-stage development. Over the next 2–6 months this necessitates new funding or partners to finance Phase 3, increasing execution risk and limiting reinvestment flexibility until cash generation or financing solutions materialize.
Dependence On External FinancingAs a pre-commercial biotech, Alterity relies on equity raises, grants and partnerships rather than product sales. This structural funding model creates recurring dilution and execution dependence on successful capital markets or non-dilutive deals, which can constrain strategic choices and shareholder returns absent clinical or partnership milestones.
Negative Returns And ProfitabilityNegative ROE and reported negative margins indicate the company has not turned R&D investment into profit. Unless clinical success translates into a commercial asset or valuable partnering/licensing deals, persistent negative returns will erode shareholder value and make long-term financing more costly.
Alterity Therapeutics News
PRNAF FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Alterity Therapeutics Ltd. lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is $53.67M.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 364 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 25, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of $0 by $0.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently Overvalued.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 10,875,416,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of $0 in its last earnings report, expectations of $0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in PRNAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
<$0.01 (-29.07% Downside)
<$0.01 (-29.07% Downside)
Blogger Sentiment
Bullish
PRNAF Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-42.68%
Trailing 12-Months
Asset Growth
134.94%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
PRNAF Stock 12 Month Forecast
Average Price Target
<$0.01
▼(-29.07% Downside)
Technical Analysis
Imugene
―
Paradigm Biopharmaceuticals
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Ownership Overview
Options Prices
Currently, No data available
---